| abstract |
Provided is a novel interleukin 2 (IL-2) mutant protein. Also provided are a fusion protein containing the IL-2 mutant protein, an immunoconjugate, a nucleic acid encoding the IL-2 mutant protein, a vector containing the nucleic acid, and a host cell. Further provided are a method for preparing the IL-2 mutant protein, a pharmaceutical composition containing the IL-2 mutant protein, and therapeutic use of the mutant protein. |